Fig. 3

Representative copy number profiles of A a WHO grade 2 IDH-mutant astrocytoma case with late recurrence and overall patient survival of greater than 9 years (conventional clinical course), B a WHO grade 2 IDH-mutant astrocytoma with rapid progression to WHO grade 4 and short patient survival, C a WHO grade 4 IDH-mutant astrocytoma, and D a WHO grade 4 IDH-wildtype glioblastoma, for comparison. “Gain” or “loss” in the copy number profiles was defined as copy number change log2 ≥ 0.3. All cases represent the initial biopsy/resection specimen before any radiation or chemotherapy was given to the patient. Copy number plots for the IDH-mutant cases are reproduced from Richardson, et al. 2017 [98] (https://www.springer.com/journal/11060) and Richardson, et al. 2019 [94] (https://academic.oup.com/jnen) and are all used here with permission